Allicin in Digestive System Cancer: From Biological Effects to Clinical Treatment

• Principais autores: Yang Zhou (Autor), Xingxuan Li (Autor), Wenyu Luo (Autor), Junfeng Zhu (Autor), Jingwen Zhao (Autor), Mengyao Wang (Autor), Lixuan Sang (Autor), Bing Chang (Autor), Bingyuan Wang (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.
• Notes: 1663-9812; 10.3389/fphar.2022.903259
• Keywords: allicin; digestive system cancer; gastrointestinal cancer; therapy; allicin secondary metabolites; Therapeutics. Pharmacology; RM1-950
• Source: Frontiers in Pharmacology, Vol 13 (2022)

Allicin is the main active ingredient in freshly-crushed garlic and some other allium plants, and its anticancer effect on cancers of digestive system has been confirmed in many studies. The aim of this review is to summarize epidemiological studies and in vitro and in vivo investigations on the anticancer effects of allicin and its secondary metabolites, as well as their biological functions. In epidemiological studies of esophageal cancer, liver cancer, pancreatic cancer, and biliary tract cancer, the anticancer effect of garlic has been confirmed consistently. However, the results obtained from epidemiological studies in gastric cancer and colon cancer are inconsistent. In vitro studies demonstrated that allicin and its secondary metabolites play an antitumor role by inhibiting tumor cell proliferation, inducing apoptosis, controlling tumor invasion and metastasis, decreasing angiogenesis, suppressing Helicobacter pylori, enhancing the efficacy of chemotherapeutic drugs, and reducing the damage caused by chemotherapeutic drugs. In vivo studies further demonstrate that allicin and its secondary metabolites inhibit cancers of the digestive system. This review describes the mechanisms against cancers of digestive system and therapeutic potential of allicin and its secondary metabolites.